A Phase 4 interventional study of valdecoxib and naproxen in Arthritis, Rheumatoid, sponsored by Pfizer. Completed at 55 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-07-21.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Arthritis, Rheumatoid by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 17th largest by enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2003, is one of 17 in phase 4, and was the 45th registered.
3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 152 studies in Arthritis, Rheumatoid by Pfizer is open now. Recruiting first, the newest first:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 18 · Phase 4 17
First in 2003; this study’s year is marked. 7 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 489 is above the median of 95 across 2,225 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 155 across the 86 interventional studies, 421 across the 63 observational. Of the 150 that completed or were terminated, 105 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe Rheumatoid Arthritis population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: naproxen
Drug: placebo
Drug: valdecoxib
valdecoxib 10 mg tablet once daily for 12 weeks
naproxen 500 mg capsule twice daily for 12 weeks
placebo tablet every morning and capsule every evening for 12 weeks
ACR-20 criteria responder
Time frame: Week 12
Patient's Global Assessment of Disease Activity
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
Duration of morning stiffness
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
Incidence and time to withdrawal due to insufficient clinical response
Time frame: Study endpoint
Physician's Global Assessment of Disease Activity
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
swollen joint count
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
Adverse events
Time frame: Baseline, Week 1, Week 6, and Week 12
Average rescue medication usage per day
Time frame: Study endpoint
Short Form-36 Acute Health Survey
Time frame: Baseline, Week 1, Week 6, and Week 12
tender joint count
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
One-Week Severity of Dyspepsia Assessment
Time frame: Baseline, Week 1, and Week 12
C-reactive protein
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
laboratory tests
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
vital signs
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
physical examinations
Time frame: Screening and Week 12
ACR-N
Time frame: Study endpoint
Patient Treatment Satisfaction Scale
Time frame: Week 1 and Week 6
Patient's assessment of arthritis pain (VAS)
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
Health Assessment Questionnaire (HAQ) Disability Index
Time frame: Screening, Baseline, Week 1, Week 6, and Week 12
The record gives a start of Feb 2003, a primary completion of Jan 2005 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valdecoxib · Naproxen